Ionis Pharmaceuticals (IONS): Can the Shares Reach the $87 Analyst Target?

Key Takeaways

• The central target of $87 is the arithmetic mean of 12 verified, current analyst price targets reviewed for this analysis.
• Those 12 targets range from roughly $66 to $104, with an independent poll of 25 analysts (S&P Global) averaging about $84.
• With shares trading near $31.50 in early November 2026, reaching $87 would require a gain of roughly 175% — a very large move.
• The strongest supports are a broad clinical pipeline (Tryngolza, Wainua, DAWNZERA and Zanvastro) and a still-substantial cash balance, against serious commercial and pipeline setbacks.
• The biggest risks are the Tryngolza sales miss and guidance cut, the failure of the pelacarsen program, and reliance on partner royalties for much of reported revenue.
• For more on the stock's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
• You can also explore Trending AI Robots to see AI-driven trading strategies currently in focus.

Analyst Price Targets and Consensus View

The $87 central target reflects the average of 12 attributable, current analyst price targets collected from sources identifying the firm, analyst, target, and date. The range is wide — roughly $66 to $104 — which itself signals genuine disagreement about how quickly Ionis Pharmaceuticals can convert its pipeline into dependable product sales. The stock carries a Buy to Strong Buy consensus, but the spread between cautious and bullish marks is unusually large.

Bullish firms such as Morgan Stanley ($104), H.C. Wainwright ($100), Bank of America ($91), and Truist ($88) emphasize the long-term commercial potential of the lipid franchise and the launch of DAWNZERA for hereditary angioedema. More cautious houses — BMO Capital, which recently upgraded the shares but carries a $66 target, and others in the $66–$79 zone — flag slower-than-expected product ramps and dependence on collaboration revenue. Many targets were lowered through the second half of 2026 after the July and September setbacks in the pelacarsen cardiovascular program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

After closing at $39.42 on November 6, 2026, the shares tumbled roughly 17–20% in early trading following Ionis's third-quarter report, to about $31.50. Reaching $87 from that level implies upside of roughly 175% — a very large move, not a routine recovery, and one that would require the stock to roughly triple from its recent lows.

The path is complicated by mixed fundamentals. Third-quarter revenue rose 55% year over year to $243 million, and the company beat EPS estimates, but Tryngolza's U.S. sales of roughly $9 million badly missed expectations of $21–27 million, prompting management to cut full-year 2026 Tryngolza guidance to about $50 million from $100–$110 million. Meanwhile, partner Novartis said it is largely abandoning pelacarsen after the Phase 3 Lp(a)HORIZON trial failed to show cardiovascular benefit, removing a royalty stream analysts had previously modeled.

What Could Support a Move Toward the Target

The bull case rests on the breadth of the pipeline rather than any single product. Tryngolza (olezarsen) remains approved for FCS (familial chylomicronemia syndrome) and sHTG (severe hypertriglyceridemia) and retains a large theoretical peak-sales opportunity, even as its launch has lagged. Wainua (with AstraZeneca) and DAWNZERA are generating product revenue, and the newly launching Zanvastro for Alexander disease adds another commercial lever. A cash balance of roughly $1.9 billion provides runway to fund development. Positive trial or launch data, or renewed revenue momentum, could support a re-rating toward higher targets. From what I see, the pipeline diversity remains a key differentiator here.

What Could Prevent the Target From Being Reached

The obstacles are substantial. Tryngolza's missed launch expectations and the cut guidance raise doubts about Ionis's independent commercial execution. The pelacarsen failure and Novartis's decision to discontinue development remove a formerly valued royalty stream and cast a shadow over similar Lp(a)-lowering approaches across the industry. Much of Ionis's reported revenue is partnership and royalty income rather than self-owned product sales, and the company continues to burn cash. Slower launches, further pipeline setbacks, or valuation compression could keep the shares far from $87.

Technical Levels and Market Structure

The stock's 52-week high of $86.50 (set in early February 2026) now stands nearly three times above the latest price, underscoring how far sentiment has deteriorated. The shares trade near their 52-week low, with initial support around the recent $31–$32 zone and the psychologically significant $30 level. On the upside, resistance begins near the prior $39–$44 consolidation area, followed by the $54–$56 and $66 levels that correspond to cautious analyst targets. A sustained move toward $87 would require reclaiming multiple prior resistance zones. I’m watching this closely as the technical setup remains fragile.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary and many targets were set before the latest Tryngolza guidance cut. Investors should watch Tryngolza's quarterly sales trajectory, any revised peak-sales commentary from management, DAWNZERA and Wainua performance, cash burn, and whether analysts revise targets downward in the wake of the third-quarter report. Regulatory and clinical updates across the pipeline remain key catalysts.

Using Tickeron’s AI Daily Buy/Sell Signals for Biotech Names

Tickeron’s AI Daily Buy/Sell Signals help me monitor volatile names like IONS by applying artificial intelligence to thousands of stocks and ETFs. The signals draw from shifting market conditions, technical behavior, and AI-driven analysis, which can be useful for spotting trend changes and managing positions in a name that has seen sharp moves this year. I find these tools add another layer when reviewing daily price action and risk levels across my watchlist.

Final Assessment

The $87 central target is the average of 12 verified analyst price targets ranging from about $66 to $104. With shares near $31.50, the required move of roughly 175% is very large, and the wide target range reflects genuine disagreement between bullish and cautious analysts. The pipeline breadth and cash runway support the higher marks, while the Tryngolza launch miss and the pelacarsen failure anchor the lower ones. Whether IONS approaches $87 will depend heavily on renewed commercial execution and pipeline delivery; no outcome is assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume